Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Non-small Cell Lung Cancer (NSCLC) in the Advanced and Adjuvant Settings

Trial Profile

A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Non-small Cell Lung Cancer (NSCLC) in the Advanced and Adjuvant Settings

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VAC 2 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 31 Jul 2019 According to an BioTime media release, the company has changed its name to Lineage Cell Therapeutics, Inc.
    • 27 Nov 2018 According to an Asterias Biotherapeutics media release, the company is planning to open the third site in this study.
    • 27 Nov 2018 According to an Asterias Biotherapeutics media release, Gary Middleton, Professor of Medical Oncology at The University of Birmingham is the Principal Investigator at Queen Elizabeth Hospital in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top